Lisata Therapeutics and Alamar Biosciences Showcase Innovative Biomarkers at AAIC 2025
- Alamar Biosciences presents groundbreaking clinical data on neurodegenerative disease biomarkers using its NULISA™ platform at AAIC 2025.
- The pTau data reveals new isoforms that can predict Alzheimer’s disease years before clinical diagnosis.
- Alamar's NULISAseq™ panel correlates pTau levels with PET imaging, enhancing early detection and therapeutic monitoring strategies.
Alamar Biosciences Unveils Groundbreaking Biomarkers at AAIC 2025
Alamar Biosciences, a frontrunner in precision proteomics, showcases transformative findings related to neurodegenerative disease biomarkers at the Alzheimer's Association International Conference (AAIC) from July 27-31, 2025, in Toronto, Canada. The company presents data from its innovative NULISA™ platform, renowned for its exceptional sensitivity, specificity, and multiplex detection capabilities. This year's conference marks a significant milestone as it features the first public presentation of clinical data generated by NULISA, focusing on brain-derived phosphorylated tau (pTau) and over 120 proteins associated with central nervous system diseases. These findings offer promising advancements in the early detection and monitoring of Alzheimer's disease and other neurodegenerative disorders.
Dr. Yuling Luo, founder, chairman, and CEO of Alamar Biosciences, emphasizes the importance of the pTau data, which demonstrates the platform's effectiveness in advancing biomarker development. Among the highlights of the presentations is the analysis of new brain-derived pTau isoforms from the 1946 Birth Cohort, illustrating their capability to predict Alzheimer's disease years before clinical diagnosis. This groundbreaking research not only enhances understanding of the disease's progression but also promises to revolutionize diagnostic strategies. The company’s NULISAseq™ CNS Disease Panel 120 serves as a pivotal tool in this endeavor, revealing significant correlations between pTau levels and amyloid and tau PET imaging results.
The presentations at AAIC 2025 also include contributions from leading experts such as Prof. Jonathan Schott from University College London and Dr. Cheryl Wellington from the University of British Columbia. Their insights further underscore the potential impact of the NULISA platform on future neurodegenerative disease research and treatment. Alamar Biosciences’ commitment to enhancing biomarker development is set to play a crucial role in improving therapeutic monitoring and early detection strategies, offering hope in the fight against Alzheimer's disease and related ailments.
In addition to the primary findings, Alamar's presentations delve into the identification of biomarkers for various neuropathologies, showcasing a unique cohort of patients with confirmed autopsy results. This comprehensive approach not only highlights the potential of the NULISA platform in advancing clinical diagnostics but also positions Alamar at the forefront of neurodegenerative research.
As the conference unfolds, the implications of these findings resonate throughout the scientific community, paving the way for innovative diagnostic and therapeutic strategies that could significantly alter the landscape of neurodegenerative disease management. Alamar Biosciences stands poised to make a lasting impact in the field, with its next-generation biomarker discovery initiatives leading the charge in combating Alzheimer's disease and its co-pathologies.